|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0025519,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0242184,
umls-concept:C0460004,
umls-concept:C0680730,
umls-concept:C0920321,
umls-concept:C1148554,
umls-concept:C1516048,
umls-concept:C1522485
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-6-13
|
|
pubmed:abstractText |
The aim of this study was to assess the pharmacokinetics, biodistribution and metabolism of [(18)F]EF3, a labelled 2-nitroimidazole hypoxia marker, in ten patients with head and neck cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1619-7070
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1282-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18317752-Adult,
pubmed-meshheading:18317752-Aged,
pubmed-meshheading:18317752-Anoxia,
pubmed-meshheading:18317752-Carcinoma, Squamous Cell,
pubmed-meshheading:18317752-Female,
pubmed-meshheading:18317752-Head and Neck Neoplasms,
pubmed-meshheading:18317752-Humans,
pubmed-meshheading:18317752-Laryngeal Neoplasms,
pubmed-meshheading:18317752-Male,
pubmed-meshheading:18317752-Middle Aged,
pubmed-meshheading:18317752-Nitroimidazoles,
pubmed-meshheading:18317752-Pharyngeal Neoplasms,
pubmed-meshheading:18317752-Positron-Emission Tomography,
pubmed-meshheading:18317752-Radiopharmaceuticals,
pubmed-meshheading:18317752-Tissue Distribution
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.
|
|
pubmed:affiliation |
Oral and Maxillofacial Surgery Department, Université catholique de Louvain, St-Luc University Hospital, 1200 Brussels, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
